课题基金 / 基金详情

Plant-based production of a vaccine against gonorrhoea

Plant-based production of a vaccine against gonorrhoea
基于植物的淋病疫苗生产
批准号:
2441454
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2020
资助国家:
英国
项目状态:
未结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
该项目涉及的BBSRC的主要优先领域是“在新的低碳生物经济中通过以生物为基础的过程和产品为可再生资源和清洁增长转型产业提供生物科学”。该项目的重点是植物生物技术,因此完全符合BBSRC的范围。该提案将介绍改进疫苗生产绩效的方法;特别是,向植物表达的过渡提供了大幅降低生产能源成本的潜力,特别是在低收入国家。此外,靶向抗原提呈细胞是一种颠覆性技术,因为它有可能超过非靶向疫苗方法,从而解决保护性免疫诱导是疫苗开发的主要障碍的疾病。淋球菌(Ng)中出现的抗菌素耐药性(AMR)使抗击这种细菌成为国际上的优先事项。NG是性传播感染(STI)的主要原因,每年导致1亿例。不能治疗Ng对女性生殖和母婴健康造成不利影响(通过盆腔炎、宫外孕、不孕症),而淋球菌感染是艾滋病毒传播的一个重要辅助因素。此外,淋球菌(GC)传播的控制受到抗生素耐药性上升的威胁。虽然疫苗是对抗耐药细菌威胁的重要方法,但GC疫苗的研究一直受到感染、抗原变异和之前失败的尝试后缺乏保护性免疫的阻碍。然而,最近的进展为疫苗的开发提供了新的动力--用于对抗脑膜炎奈瑟菌的外膜囊泡疫苗(OMV)与对Ng的适度但显著的保护有关,这表明了一种识别保护性抗原的方法。基于单个重组Ng抗原的疫苗接种策略在小鼠感染模型和临床试验中都取得了有限的成功。一种新的方法是使用病毒样颗粒(VLP)--或最近引入的大的、合成的大分子组件--作为抗原传递的平台。这些发展为疫苗设计提供了迄今尚未开发的潜力。此外,德里克实验室最近开发了一种技术,可以将任何数量的抗原融合到特定的VLP或组件上。关键的是,这种方法还可以方便地融合单抗:结合针对表面受体的抗体,从而可以靶向树突状细胞或其他抗原提呈细胞的特定亚群。这一发展承诺了一种改变游戏规则的疫苗设计方法,将靶向驱动的抗体治疗技术与传统疫苗设计相结合。它可以提供所需的突破,以绕过针对Ng再次感染的弱保护性免疫的挑战。此外,人们对将植物表达系统用于生物制药和疫苗越来越感兴趣,特别是在发展中国家的应用。因此,该项目旨在开发Anil Day开发的基于叶绿体的表达方法,这种方法能够获得非常高的重组蛋白产量,并将其应用于修饰的VLP、组件和Ng抗原。
英文摘要
The principal BBSRC priority area addressed by this project is 'Bioscience for renewable resources and clean growth - transforming industries through bio-based processes and products in a new low-carbon bioeconomy'. The project has a focus on plant biotechnology and therefore fits firmly within the BBSRC ambit. The proposal will introduce ways to improve the performance of vaccine production; in particular, transition to plant-based expression offers the potential for much reduced production energy costs, particularly in low income countries. Further, the targeting of antigen presenting cells is a disruptive technology, in the sense that it has the potential to overtake non-target vaccine approaches and thus address disease where induction of protective immunity is a major roadblock to vaccine development. The emergence of antimicrobial resistance (AMR) in Neisseria gonorrhoeae (Ng) has made combatting this bacterium an international priority. Ng is a leading cause of sexually transmitted infection (STI), responsible for >100 million cases annually. The inability to treat Ng adversely impacts female reproductive and foeto-maternal health (through pelvic inflammatory disease, ectopic pregnancy, infertility), while gonococcal infection is an important co-factor for HIV transmission. Furthermore, control of the gonococcal (Gc) transmission is threatened by the rise in antibiotic resistance. While vaccines are an important approach against the threat of resistant bacteria, Gc vaccine research has been hampered by the lack of protective immunity following infection, antigenic variation and previous failed attempts. However, recent advances have provided fresh impetus for vaccine development- an outer membrane vesicle vaccine (OMV) used against Neisseria meningitidis was associated with a modest yet significant protection against Ng, suggesting an approach to identify protective antigens. Vaccination strategies based on single recombinant Ng antigens have met with limited success, both in mouse infection models and clinical trials. A novel approach would be to use virus-like particles (VLPs)- or the more recently introduced large, synthetic macromolecular assemblies- as platforms for antigen delivery. These developments offer a hitherto untapped potential in vaccine design. In addition, the Derrick lab has recently developed a technology which allows the fusion of any number of antigens to a specific VLP or assembly. Critically, the method also allows for facile fusion of monoclonal antibodies: incorporation of antibodies directed against surface receptors thus allows targeting against specific subsets of dendritic or other antigen presenting cells. This development promises a game-changing approach to vaccine design, by combining target-driven antibody therapeutic technologies with traditional vaccine design. It could provide the breakthrough needed to circumvent the challenge of weak protective immunity against Ng reinfection. In addition, there is increasing interest in the use of plant-based expression systems for biopharmaceuticals and vaccines, particularly for application in developing countries. This project therefore aims to exploit methods developed by Anil Day for plastid-based expression, which enables very high yields of recombinant proteins, and apply them to modified VLPs, assemblies and Ng antigens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Data-driven Recommendation System Construction of an Online Medical Platform Based on the Fusion of Information
Incentive and governance schenism study of corporate green washing behavior in China: Based on an integiated view of econfiguration of environmental authority and decoupling logic
  • 批准号:
    --
  • 项目类别:
    外国学者研究基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    YU BYUNGJUN
  • 依托单位:
Exploring the Intrinsic Mechanisms of CEO Turnover and Market Reaction: An Explanation Based on Information Asymmetry
  • 批准号:
    W2433169
  • 项目类别:
    外国学者研究基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    HAOFEI ZHANG
  • 依托单位:
含Re、Ru先进镍基单晶高温合金中TCP相成核—生长机理的原位动态研究
  • 批准号:
    52301178
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    夏万顺
  • 依托单位: